BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJM, Guest PC, Rahmoune H, Steiner J, Bahn S. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun 2016;52:178-86. [PMID: 26541453 DOI: 10.1016/j.bbi.2015.10.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Brown JS. Treatment of cancer with antipsychotic medications: Pushing the boundaries of schizophrenia and cancer. Neurosci Biobehav Rev 2022;141:104809. [PMID: 35970416 DOI: 10.1016/j.neubiorev.2022.104809] [Reference Citation Analysis]
2 Lago SG, Tomasik J, van Rees GF, Rustogi N, Vázquez-Bourgon J, Papiol S, Suarez-Pinilla P, Crespo-Facorro B, Bahn S. Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. Brain Behav Immun 2022;103:37-49. [PMID: 35381347 DOI: 10.1016/j.bbi.2022.03.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lago SG, Bahn S. The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. NPJ Genom Med 2022;7:25. [PMID: 35338153 DOI: 10.1038/s41525-022-00290-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lago SG, Tomasik J, van Rees GF, Rubey M, Gonzalez-vioque E, Ramsey JM, Haenisch F, Broek JA, Vázquez-bourgon J, Papiol S, Suarez-pinilla P, Ruland T, Auyeug B, Mikova O, Kabacs N, Arolt V, Baron-cohen S, Crespo-facorro B, Bahn S. Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. Brain, Behavior, and Immunity 2021;91:673-82. [DOI: 10.1016/j.bbi.2020.07.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Garcia-rosa S, Carvalho BS, Guest PC, Steiner J, Martins-de-souza D. Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. Journal of Proteomics 2020;224:103813. [DOI: 10.1016/j.jprot.2020.103813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lago SG, Tomasik J, van Rees GF, Steeb H, Cox DA, Rustogi N, Ramsey JM, Bishop JA, Petryshen T, Haggarty SJ, Vázquez-Bourgon J, Papiol S, Suarez-Pinilla P, Crespo-Facorro B, van Beveren NJ, Bahn S. Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Sci Adv 2019;5:eaau9093. [PMID: 31086815 DOI: 10.1126/sciadv.aau9093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
7 Cooper JD, Han SYS, Tomasik J, Ozcan S, Rustogi N, van Beveren NJM, Leweke FM, Bahn S. Multimodel inference for biomarker development: an application to schizophrenia. Transl Psychiatry 2019;9:83. [PMID: 30745560 DOI: 10.1038/s41398-019-0419-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lago SG, Bahn S. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. ACS Chem Neurosci 2019;10:58-78. [PMID: 29944339 DOI: 10.1021/acschemneuro.8b00205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
9 Aquino A, Alexandrino GL, Guest PC, Augusto F, Gomes AF, Murgu M, Steiner J, Martins-de-Souza D. Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. Front Psychiatry 2018;9:209. [PMID: 29887809 DOI: 10.3389/fpsyt.2018.00209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
10 Steiner J, Guest PC, Martins-de-Souza D. Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients. Adv Exp Med Biol 2017;974:3-19. [PMID: 28353222 DOI: 10.1007/978-3-319-52479-5_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Turck CW, Guest PC, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F, Martins-de-Souza D. Proteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response. Front Mol Neurosci 2017;10:272. [PMID: 28912679 DOI: 10.3389/fnmol.2017.00272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Guest PC, Guest FL, Martins-de Souza D. Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research. Int J Neuropsychopharmacol 2016;19:pyv138. [PMID: 26721951 DOI: 10.1093/ijnp/pyv138] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]